Myriad Reaches Settlements Over Breast Cancer Test
Myriad Genetics has settled or is in the process of settling various patent infringement lawsuits it had filed against companies offering tests to screen for increased breast cancer risks, according to a company spokesperson. So far, Myriad spokesperson Ronald Rogers said settlements have been reached with LabCorp, Invitae and Pathway Genomics. Meanwhile, the company is in settlement negotiations with Ambry, Counsyl, GeneDx and Quest Diagnostics.
- "Myriad Genetics Ending Patent Dispute on Breast Cancer Risk Testing"(Pollack, New York Times, 1/27).